Patients with ASA PS 1-3, scheduled for surgery under total intravenous anesthesia
Conditions
Interventions
(1) Manually controlled group (Group H): Attending anesthesiologist will start the administration of the circulatory agonists (by injection or by continuous infusion) when the measured blood pressure
Sponsors
Nagata Osamu
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Males and females patients over 20 years old at the time of informed consent (2) Patients with ASA Physical Status of 1, 2, and 3 who are scheduled for surgery under general anesthesia with propofol, remifentanil, and rocuronium (3) Patients who understand the contents of this study and are willing to provide written informed consent for participation in this study
Exclusion criteria
Exclusion criteria: (1) Patients with a history of hypersensitivity to propofol, remifentanil, rocuronium, sugammadex, circulatory agonists (phenylephrine, noradrenaline, etc.), or infusion products (2) Patients who cannot have a bispectral index ("BIS") sensor applied intraoperatively (3) Patients who cannot receive additional doses of rocuronium after the initial single dose (4) Patients who cannot have their blood pressure measured non-invasively during surgery (5) Patients undergoing surgery with hypothermia (6) Patients undergoing cardiovascular surgery (7) Patients who are pregnant or lactating (8) Patients with severely depressed cardiac function (EF less than 40%) or with ventricular tachycardia, or a history of coronary intervention within the last 3 months (9) Patients who are determined not to be eligible for participation in this study by the research director
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of time that mean blood pressure was maintained at 65 mmHg or higher, and systolic blood pressure at 140 mmHg or lower during the evaluation period | — |
Secondary
| Measure | Time frame |
|---|---|
| (1) Percentage of time with abnormally low blood pressure (mean blood pressure 140 mmHg) during the evaluation period (3) Cardiovascular parameters by esCCO (CO, CI,SV, SVI) during the evaluation period (4) Percentage of patients who received noradrenaline during the evaluation period (5) Number (percentage) and average number of additional doses of circulatory agonists administered by the anesthesiologist during the evaluation period (autoregulation group only) (6) Total dose and hourly dose of circulatory agonists and infusions during the evaluation period (7) The percentage of time during which adequate anesthesia was achieved from the start of surgery to the end of surgery (adequate anesthesia range time) (8) Average and standard deviation, quartiles, and interquartile range of mean blood pressure during the evaluation period | — |
Contacts
Public ContactOsamu Nagata
Center Hospital of the National Center for Global Health and Medicine
Outcome results
None listed